Publications

Friedes C, Iocolano M, Yegya-Raman N, Kucharczuk JC, Pechet TTV, Cohen RB, Aggarwal C, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, D'Avella C, Singh AP, Davis CW, Langer CJ, Bradley J, Feigenberg SJ. Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy. Am J Clin Oncol. 2025 Nov 10. doi: 10.1097/COC.0000000000001260. Epub ahead of print. PMID: 41198094.

Wang W, Scholes D, Roy M, Singhal S, Kucharczuk J, Jarrar D, Predina J, Pechet T, Sun L, Singh AP, Cohen RB, Langer CJ, Aggarwal C, Marmarelis ME: EMBER-Lung: Electronic medical record boosting molecular testing in early stage NSCLC. Journal of Clinical Oncology 43(16 Suppl), June 2025 Notes: Presented at the 2025 American Society of Clinical Oncology ASCO Annual Meeting I, Chicago, IL, May/June 2025.

Jeffrey C. Thompson, Caitlin Tilsed, Christiana Davis, Aasha Gupta, Bihui Melidosian, Chifei Sun, Michael E. Kallen, Cynthia Timmers, Corey J. Langer and Steven M. Albelda. Predictive Signatures for Responses to Checkpoint Blockade in Small-Cell Lung Cancer in Second-Line Therapy Do Not Predict Responses in First-Line Patients. Cancers 2024, 16, 2795. https://doi.org/10.3390/cancers16162795

Divij Mathew, Melina E. Marmarelis, Caitlin Foley, Joshua M. Bauml, Darwin Ye, Reem Ghinnagow, Shin Foong Ngiow, Max Klapholz, Soyeong Jun, Zhaojun Zhang, Robert Zorc, Christiana W. Davis, Maximillian Diehn, Josephine R. Giles, Alexander C. Huang, Wei-Ting Hwang, Nancy R. Zhang, Adam J. Schoenfeld, Erica L. Carpenter, Corey J. Langer, E. John Wherry, Andy J. Minn. Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients. Science. 21 Jun 2024. Vol 384, Issue 6702. DOI: 10.1126/science.adf1329.

David J. Cantor, MD, PhD, Christiana Davis, MD, Christine Ciunci, MD, MSCE, Charu Aggarwal, MD, MPH, Tracey Evans, MD, Roger B. Cohen, MD, Joshua M. Bauml, MD, Corey J. Langer, MD. Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC. JTO Clin Res Rep. 2024;5:100667.

Cole Friedes, Nikhil Yegya-Raman, Siqi Zhang, Michelle Iocolano, Roger B. Cohen, Charu Aggarwal, Jeffrey C. Thompson, Melina Elpi Marmarelis, William C. Levin, Keith A. Cengel, Christine Agnes Ciunci, Aditi Puri Singh, Christopher Davella, Christiana Davis, Corey J. Langer, and Steven J Feigenberg. Patterns of failure in metastatic non-small cell lung cancer (mNSCLC) treated with first line pembrolizumab and use of local therapy in patients with oligoprogression. Clinical Lung Cancer (2023) https://doi.org/10.1016/j.cllc.2023.09.002

Jennifer G. Whisenant, PhD,Javier Baena, MD, Alessio Cortellini, MD, Li-Ching Huang, PhD,Giuseppe Lo Russo, MD, PhD, Luca Porcu, PhD, Selina K. Wong, MD, Christine M. Bestvina, MD, Matthew D. Hellmann, MD, Elisa Roca, MD, PhD, Hira Rizvi, MD, Isabelle Monnet, MD, Amel Boudjemaa, MD, Jacobo Rogado, MD, Giulia Pasello, MD, PhD,Natasha B. Leighl, MD, Oscar Arrieta, MD, Avinash Aujayeb, MBBS, Ullas Batra, MD, Ahmed Y. Azzam, MD, Mojca Unk, MD, MSc, Mohammed A. Azab, MD, Ardak N. Zhumagaliyeva, MD, PhD, Carlos Gomez-Martin, MD, Juan B. Blaquier, MD, Erica Geraedts, MD, Giannis Mountzios, MD, PhD, Gloria Serrano-Montero, MD, Niels Reinmuth, MD, Linda Coate, MD, Melina Marmarelis, MD, Carolyn J. Presley, MD, MHS, Fred R. Hirsch, MD, Pilar Garrido, MD, PhD, Hina Khan, MD, Alice Baggi, MD,Celine Mascaux, MD, Balazs Halmos, MD, Giovanni L. Ceresoli, MD, Mary J. Fidler, MD, Vieri Scotti, MD, Anne-Cécile Métivier, MD, Lionel Falchero, MD, Enriqueta Felip, MD, PhD, Carlo Genova, MD, PhD, Julien Mazieres, MD, PhD, Umit Tapan, MD, Julie Brahmer, MD, Emilio Bria, MD, Sonam Puri, MD, Sanjay Popat, MD, Karen L. Reckamp, MD, Floriana Morgillo, MD, PhD, Ernest Nadal, MD, PhD, Francesca Mazzoni, MD, Francesco Agustoni, MD, Jair Bar, MD, Federica Grosso, MD, Virginie Avrillon, MD, Jyoti D. Patel, MD, Fabio Gomes, MD, Ehab Ibrahim, MD, Annalisa Trama, PhD, Anna C. Bettini, MD, Fabrice Barlesi, MD, PhD. A Definitive Prognostication System for Patients With Thoracic Malignancies

Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. J Thorac Oncol. 2022 May; 17(5): 661–674.
Kathryn F Mileham, Suanna S Bruinooge, Charu Aggarwal, Alicia L Patrick, Christiana Davis, Daniel J Mesenhowski, Alexander Spira, Eric J Clayton, David Waterhouse, Susan Moore, Abdul-Rahman Jazieh, Ronald C Chen, Melinda Kaltenbaugh, Jen Hanley Williams, Julie R Gralow, Richard L Schilsky, Elizabeth Garrett-Mayer. Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. JCO Oncol Pract 2022 Apr;18(4):e426-e441. doi: 10.1200/OP.21.00394. Epub 2021 Oct 25.

Predina JD, Haas AR, Martinez M, O’Brien Shaun S, Moon EK, Woodruff P, Stadanlick J, Corbett C, Frenzel-Sulyok L, Bryski MG, Eruslanov E, Deshpande C, Langer C, Aguilar LK, Guzik BW, Manzanera AG, Aguilar-Cordova E, Singhal S, Albelda SM. Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity. Mol Therapy 2021 29: 658-670.

Lova Sun MD, Sanjna Surya BS, Noah G. Goodman MPH, Anh N. Le BS, Gregory Kelly MS, Olutosin Owoyemi BS, Heena Desai MS, Cathy Zheng BS, Shannon DeLuca BS, Madeline L. Good BS, Jasmin Hussain BS, Seth D. Jeffries BS, Yolanda R. Kry BS, Emily M. Kugler BS, Maikel Mansour MPH, John Ndicu AS, AnnaClaire Osei-Akoto BA, Timothy Prior BS, Stacy L. Pundock BA, Lisa A. Varughese PharmD, JoEllen Weaver BS, Abigail Doucette MPH, Scott Dudek BA, Shefali Setia Verma MS, Sigrid Gouma PhD, Madison E. Weirick BS, Christopher M. McAllister BS, Erin Bange MD, Peter Gabriel MD, Marylyn Ritchie PhD, Daniel J. Rader MD, Robert H. Vonderheide MD DPhil, Lynn M Schuchter MD, Anurag Verma PhD, Ivan Maillard MD PhD, Ronac Mamtani MD MSCE, Scott E. Hensley PhD, Robert Gross MD MSCE, E. Paul Wileyto PhD, Alexander C. Huang MD, Kara N. Maxwell MD PhD, Angela DeMichele MD MSCE. SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapy. JCO Oncol Pract. 2021 Dec;17(12): e1879-e1886. doi: 10.1200/OP.21.00113. Epub 2021 Jun 16.

Robert H Vonderheide, Kimberly A Kraynyak , Anthony F Shields, Autumn J McRee, Jennifer M Johnson, Weijing Sun, Ashish V Chintakuntlawar, Jan Pawlicki, Albert J Sylvester, Trevor McMullan, Robert Samuels, Joseph J Kim, David Weiner, Jean D Boyer, Matthew P Morrow, Laurent Humeau, Jeffrey M Skolnik. Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors. Journal for ImmunoTherapy of Cancer 2021;9: e003019. doi:10.1136/jitc-2021-003019

Lova Sun, Christiana W. Davis, Wei-Ting Hwang, Seth Jeffries, Lydia Frenzel Sulyok, Melina E. Marmarelis, Aditi P. Singh, Abigail T. Berman, Steven J. Feigenberg, William Levin, Christine A. Ciunci, Joshua M. Bauml, Roger B. Cohen, Corey J. Langer, Charu Aggarwal. Outcomes in Patients With Non–small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy. Clinical Lung Cancer, Volume 22, Issue 1,2021, Pages 58-66. e3.

Katz SI, Roshkovan L, Berger I, Friedberg JS, Alley EW, Simone, II CB, Haas AR, Cengel KA, Sterman DH, Albelda SM. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial. January 2021 Lung Cancer 154(10)

Klampatsa A, Dimou V, Albelda SM. Mesothelin-Targeted CAR-T Cell Therapy for Solid Tumors. Expert Opinion on Biological Therapy. 2020; DOI: 10.1080/14712598.2021.1843628

Thompson JC, Davis C, Deshpande C, Hwang W-T, Jeffries S, Huang A, Mitchell TC, Langer CJ, Albelda SM. A gene signature of antigen processing and presentation machinery (APM) predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. Journal for ImmunoTherapy of Cancer 2020;8: e000974.

Klampatsa A, Albelda SM. Current Advances in CAR T Cell Therapy for Malignant Mesothelioma. J. Cellular Immunology, 2020; 2(4):192-200.

Klampatsa A, Liebowitz MS, Sun J, Liousia M, Arguiri E, Albelda SM. Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model. Molecular Therapy-Oncolytics, 2020 Jul; 18:360-371, doi: 10.1016/j.omto.2020.07.005. PMID 32802940. PMC7417672.

Thompson JC, Hwang W-T, Davis C, Deshpande C, Jeffries S, Rajpurohit Y, Krishna V, Smirnov D, Verona R, Lorenzi MV, Langer CJ, Albelda SM. Gene Signatures of Tumor Inflammation and Epithelial-to-Mesenchymal Transition (EMT) Predict Responses to Immune Checkpoint Blockade in Lung Cancer with High Accuracy. Lung Cancer 2020 Jan; 139:1-8, doi: 10.1016/j.lungcan.2019.10.012. PMID 31683225. PMC7176049.

Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Mol Ther. 2019 Nov 6; 6:27(11):1919-1929. doi: 10.1016/j.ymthe.2019.07.015. PMID: 31420241. PMC683887.

Joshua Bauml, MD; Rosemarie Mick, MS; Christine Ciunci, MD, MSCE; Charu Aggarwal, MD, MPH; Christiana Davis, MD; Tracey Evans, MD; Charuhas Deshpande, MD; Linda Miller, RN; Pooja Patel; Evan Alley, MD, PhD; Christina Knepley, CRNP; Faith Mutale, CRNP; Roger B. Cohen, MD; Corey J. Langer, MD. Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer. A Phase 2 Trial. JAMA Oncol. 2019;5(9):1283-1290. doi:10.1001/jamaoncol.2019.1449

Kargl J, Zhu X, Zhang H, Yang GHY, Friesen TJ, Shipley M, Maeda DY, Zebala JA, McKay-Fleisch J, Meredith G, Mashadi-Hossein A, Baik C, Pierce RH, Redman MW, Thompson JC, Albelda SM, Bolouri H, Houghton AM. Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight. 2019 Dec 19;4(24): e130850. doi: 10.1172/jci.insight.130850, PMID: 31852845, PMC6975266.

O’Brien SM, Klampatsa A, Thompson JC, Martinez MC, Hwang WT, Rao AS, Standalick JE, Kim S, Cantu E, Litzky LA, Singhal S, Eruslanov E, Moon EK, Albelda SM. Function of Human Tumor-Infiltrating Lymphocytes in Early Stage Non-Small Cell Lung Cancer. Cancer Immunology Research,2019; 7:896-909. PMID 31053597. PMC6548666.

Charu Aggarwal, Christiana W. Davis, Rosemarie Mick, and Jeffrey C. Thompson, Saman Ahmed, Seth Jeffries, Stephen Bagley, Peter Gabriel, Tracey L. Evans, Joshua M. Bauml, Christine Ciunci, Evan Alley, Jennifer J.D. Morrissette, Roger B. Cohen, Erica L. Carpenter, and Corey J. Langer. Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non–Small-Cell Lung Cancer. JCO Precision Oncology, August 2018; DOI: 10.1200/PO.18.00107.

Bengsch B, Ohtani T, Khan O, Setty M, Manne S, O'Brien S, Gherardini PF, Herati RS, Huang AC, Chang KM, Newell EW, Bovenschen N, Pe'er D, Albelda SM, Wherry EJ. Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity. 2018;48(5):1029-1045. PMID: 29768164 PMCID: PMC6010198.

Aggarwal C, Haas AR, Metzger S, Aguilar LK, Aguilar-Cordova E, Manzanera AG, Gómez-Hernández G, Katz SI, Alley EW, Evans TL, Bauml JM, Cohen RB, Langer CJ, Albelda SM, Sterman DH. Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion. Mol Ther. 2018, 26(5):1198-1205. PMID 29550074 PMCID: PMC5993936.

Scherpereel A, Wallyn F, Albelda SM, Munck C. Novel Therapies for Mesothelioma. Lancet Oncol 2018, 19: e161-172.

Singhal S, Standanlick J, Annunziata M, Rao A, Bhojjagarwala P, O’Brien S, Moon EK, Cantu E, Danet-Desnoyers G, Ra H-J, Litzky L, Akimova T, Beier UH, Hancock, Albelda SM, Eruslanov EB. Human tumor-associated monocytes/macrophages and their regulation of the tumor-specific effector T cell responses in
early-stage lung cancer: role of macrophage- versus tumor-expressed PD-L1. Science Transl Med, 2018, 13:11(479).

Aggarwal C, Wang X, Ranganathan A, Torigian D, Troxel A, Evans T, Cohen RB, Vaidya B, Rao C, Connelly M, Vachani A, Langer C, Albelda S. Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy. Lung Cancer. 2017, 112:118-125.

Akimova T, Zhang T, Negorev D, Singhal S, Stadanlick J, Rao A, Annunziata M, Levine MH, Beier UH, Diamond JM, Christie JD, Albelda SM, Eruslanov EB, Hancock WW. Human lung tumor FOXP+ Tregs upregulate four “Treg-locking” transcription factors. JCI Insight 2017;2(16): e94075. https://doi.org/10.1172/jci.insight.94075.

Bagley SJ, Kothari S, Aggarwal C, Bauml J, Alley E, Evans TL, Kosteva J, Ciunci C, Gabriel P, Thompson J, Stonehouse-Lee S, Sherry VE, Gilbert E, Sandy BE, Mutale F, DiLullo G, Cohen R, Vachani A, Langer CJ. Pretreatment neutrophil-to-lymphocyte ratio as a marker ofoutcomes in nivolumab-treated patients with advancednon-small-cell lung cancer. Lung Cancer 2017, 106: 1–7.

Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, Tcyganov E, Hashimoto A, Nefedova Y, Lin C, Partlova S, Garfall A, Vogl DT, Xu X, Knight SC, Malietzis G, Lee GH, Eruslanov E, Albelda SM, Wang X, Mehta JL, Bewtra M, Rustgi A, Hockstein N, Witt R, Masters G, Nam B, Smirnov D, Sepulveda MA, Gabrilovich DI. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol. 2016 Aug;1(2). pii: aaf8943. doi: 10.1126/sciimmunol. aaf8943. Epub 2016 Aug 5. PMID: 28417112.

Chen X, Yang Y, Berger I, Khalid U, Patel A, Cai J, Farwell MD, Langer C, Aggarwal C, Albelda SM, Katz SI. Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging. Oncotarget 2016 Sep 16, Epub ahead of print.

Newick K, O’Brien S, Sun J, Kapoor V, Maceyko S, Lo A, Pure E, Moon E, Albelda SM. Augmentation of CAR T cell trafficking and antitumor efficacy by blocking protein kinase A (PKA) localization. Cancer Immunology Research, 2016 6:541-51.

Sterman DH, Alley E, Stevenson JP, Friedberg J, Metzger S, Recio A, Moon EK, Haas AR, Vachani A, Katz SI, Sun J, Heitjan D, Hwang, WT, Litzky L, Yearley JH, Tan KS, Papasavvas E, Kennedy P, Montaner L, Cengel KA, Simone CB, Culligan M, Langer CJ, Albelda SM. Pilot and Feasibility Trial of Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-Interferon-alpha Combined with Chemotherapy. Clinical Cancer Research, 2016 22:3791-800.

Newick K, Moon E, Albelda SM. CAR T Cell Therapy For Solid Tumors. Molec Therapy Oncolytics, 2016 Apr 13;3:16006.

Singhal S, Bhojnagarwala PS, O’Brien S, Moon EK, Garfall AL, Rao A, Quatromoni JG, Stephen TL, Litzky L, Deshpande C, Feldman M, Hancock WW, Conejo-Garcia JR, Albelda SM, Eruslanov EB. Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen Presenting Cell Features (Hybrid TANs) in Early-Stage Human Lung Cancer. Cancer Cell, 2016, 30:120-35.

Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, Newick K, Lo A, June CH, Zhao Y, Moon EK. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016; 76: 1578-90.

Moon EK, Ranganathan R, Eruslanov E, Kim S, Newick K, O'Brien S, Lo A, Liu X, Zhao Y, Albelda SM. Blockade of Programmed Death 1 Augments the Ability of Human T cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin Cancer Res. 22: 436-447, 2016 PMCID: PMC4715990.

Quatromoni J, Singhal S, Bhojnagarwala P, Hancock WW, Albelda SM, Eruslanov E. An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells. J Leukoc Biol. 97:201-9, 2015. PMID: 25359999.

Lo A, Wang LC, Scholler J, Monslow J, Avery D, Newick K, O'Brien S, Evans RA, Bajor DL, Clendenin C, Durham AC, Buza EL, Vonderheide RH, June CH, Albelda SM, Pure E. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res. 75:2800-10. 2015. PMCID: PMC4506263.

Fridlender ZG, Albelda SM, Granot Z. Promoting metastasis: neutrophils and T cells join forces. Cell Res.25:765-6, 2015. PMCID: PMC4493274.

Beatty, G.L., Haas, A.R., Maus M.V., Torigian, D.A., Soulen, M.C., Piesa, G., Chew, A., Zhao, Y., Levine B.L., Albelda,S.M., Kalos, M., June, C.H. Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T cells Induce Anti-Tumor Activity in Solid Malignancies. Cancer Immunology Research, 2:112-120. 2014. PMCID: PMC3932715.

Wang, LC., Lo, A., Scholler, J., Sun, Majumdar, R.S., Kapoor, V., Antziz, M., Cotner, C., Johnson, L.A. Durham, A.C., Solomides C.C., June, C.H., Pure, E., Albelda, S.M., Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity Without Severe Toxicity. Cancer Immunology Research, 2:154-166, 2014. PMCID: PMC4007316

Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM. Multifactorial T cell Hypofunction that is Reversible Can Limit the Efficacy of Chimeric Antibody Receptor-transduced Human T cells in Solid Tumors. Clinical Cancer Res 20:4262-4273.2014. PMCID: PMC4134701.

Eruslanov EB, Bhojnagarwala, P.S., Quatromoni, J.G., Stephen, T.L., Ranganathan, A, Deshpande, C., Akimova, T, Vachani, A., Litzky, L., Hancock W., Conejo-Garcia, J.R., Feldman, M., Albelda, S.M., Singhal, S. Tumor-Associated Neutrophils Stimulate T Cell Responses in Early Stage Human Lung Cancer, J. Clinical Investigation, 124:5466-80. 2014. PMCID: PMC4348966.

Beatty GL, Moon EK. Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. Oncoimmunology. 2014 Dec 21; 3(11): e970027.

Albelda S.M., Thorne S.H. Giving Oncolytic Viruses more BiTE. Molecular Therapy 22:6-8, 2014. PMCID: PMC3978795.

Philanthropic support is catalytic. It closes the gap between curiosity and clinical impact, empowering us to deliver on the promise of personalized, biomarker-informed lung cancer care. Join us! — Donate Today!

Donate Today!